[ad_1]
Gilead Sciences, the American drug maker, said it is willing to partner with governments, pharmaceutical companies, including India. In an interview with Moneycontrol, he said he was also studying patent accumulation to increase capacity and ensure the accessibility of his antiviral drug Remdesivir to Covid-19 sufferers worldwide.
“On the supply side, we are working to build a global consortium of pharmaceutical and chemical product manufacturers to expand global capacity and production and we are committed to donating all of our existing supply to patients in need,” said Moneycontrol. quoting the Gilead spokesperson.
The spokesperson added that it will be essential for countries to work together to create a supply chain for people around the world.
“… We look forward to these collaborative efforts. In the event of regulatory action, we are in talks with various groups on how we could bring Remdesivir to the developing world, “said Gilead.
The drug maker, however, did not give any timeline for its launch in India.
The company also did not mention whether an Indian generic drug firm had reached the consortium. But since Gilead in the past used voluntary licenses to get Indian companies to manufacture and release HIV and hepatitis C drugs in low- and middle-income countries (LMICs), the possibility cannot be ruled out.
In particular, Remdesivir has shown positive results in two clinical trials, one conducted by the company and one by the US government. USA In the treatment of patients with severe cases of Covid-19. But the results of a randomized, controlled study of Redemisivir, conducted in Wuhan, China, did not show any statistically significant clinical benefit of the drug. After the study was launched, Dr. Anthony S Fauci, Director of the National Institute of Allergy and Infectious Diseases, said Remdesivir decreased recovery time among patients, the first results of a clinical trial showed.
Gilead added that the findings from the recently released trials will open up several opportunities to inspect Remdesivir’s potential.
“Our teams will look for ways to bring the treatment to a broader patient population by researching other formulations and means of administration,” said the drug maker. He added that I would engage with partners to see how Remdesivir could work with other therapies.
Gilead said that India is not on the Compassionate Use program for Remdesivir. A compassionate use is to use a new unapproved medication to treat a seriously ill patient in a setting where no other treatment is available.
The company said that those who suffer from Covid-19 in India would have to enroll in the World Health Organization’s Solidarity trial.
“India is part of the large global study designed by the WHO: the Solidarity trial. This trial is the best way for patients to access Remdesivir, allowing access to Remdesivir and collecting data to inform the use of this compound in research and to support possible regulatory approvals that may allow for wider use of Remdesivir, “the spokesperson said.
Support the daily wage earners who have been most affected by the COVID-19 crisis. Click here to contribute to the cause. #IndiaGives
The Daily Bulletin News18 Coronavirus COVID-19: Get your copy here.
Subscribe to News18 Daybreak. Follow us Twitter,
Instagram
Facebook,
Telegram,
TikTok and in
Youtube
First Anniversary Offer: Sign up for the Moneycontrol PRO Annual Plan for ₹ 1 / – per day for the first year and claim exclusive benefits worth ₹ 20,000. Coupon Code: PRO365
[ad_2]
